CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma

Abstract

Aberrant expression of CK20 and Ki-67 has been documented in many kinds of primary tumors and has proved useful as an ancillary diagnostic aid for those tumors. The aim of this study was to analyze the expression patterns of CK20 and Ki-67 in human bladder carcinomas (BCa) and to evaluate their clinical significance in the progression of BCa. CK20 and Ki-67 expression in BCa and normal bladder tissues were detected by immunohistochemical staining. The Spearman correlation was calculated between the expression of CK20 and Ki-67 in BCa tissues. The correlation of CK20 and Ki-67 expression with the clinicopathological characteristics and the prognosis of BCa were subsequently assessed. CK20 expression was positively expressed in 103/154 (66.9%) of BCa and 2/30 (6.67%) of normal bladder tissues, respectively. The positive expression rate of Ki-67 in BCa tissues was also significantly higher than those in normal bladder tissues (81.8 vs. 10%, p < 0.01). The Spearman analysis indicated that the expression level of CK20 has a significant positive correlation with that of Ki-67 (rs = 0.86, p = 0.02). Pathologic findings demonstrated that the intensity of CK20 and Ki-67 staining in cancerous tissues was associated significantly with tumor grades (p = 0.03, p < 0.01), distant metastasis (both p < 0.01) and TNM grades (p = 0.01, p = 0.03) of BCa. The progression-free survival of the patients with CK20 (+)/Ki-67 (+) expression was poorest (p < 0.01). The results suggest that the expression of CK20 and Ki-67 may be an important feature of BCa, and the detection of their co-expression may benefit the prediction of BCa prognosis.

Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis

“…In our experimental model, altered CK14/20 staining was associated with multiple preneoplastic and neoplastic lesions. This agrees with the findings from clinical studies correlating aberrant CK14/20 staining with worsened prognostic in patients with bladder cancer (Ramos et al 2003;Ye et al 2010;Volkmer et al 2012;Otto et al 2013). The present results may also support the use of CK20 for distinguishing neoplastic and preneoplastic foci from some reactive lesions, as previously proposed (Edgecombe et al 2012;Amin et al 2014).…”

“…Ramos et al (2003) described an association between increased CK20 expression and disease recurrence in patients with low-grade papillary tumours. Aberrant CK20 expression was also correlated with increased Ki-67 counts, as well as with tumour stage, histological grade, the presence of metastasis and reduced progression-free survival (Ye et al 2010). Otto et al (2013) recently reported that increased CK20 expression correlated with shorter recurrence-free survival in patients with T1 urothelial bladder carcinoma.…”

“…Aberrant CK20 expression was also correlated with increased Ki‐67 counts, as well as with tumour stage, histological grade, the presence of metastasis and reduced progression‐free survival (Ye et al . ). Otto et al .…”

Immunocytochemical staining for p53 and Ki‐67 helps to characterise urothelial cells in urine cytology

“…Using biopsy specimens, previous studies have identified certain immunomarkers as potential predictive markers for recurrence or as prognostic indicators of the severity of disease. Among these markers, p53 and Ki‐67 have been investigated in detail . Ki‐67 is a nuclear antigen present in all cycling human cells and is a marker of active cell proliferation.…”

Fibroblast growth factor receptor 1 and cytokeratin 20 expressions and their relation to prognostic variables in bladder cancer

“…Rajcani et al, (2013) found that CK20 was present in all invasive tumors. Ye et al, (2010) demonstrated that the intensity of CK20 and Ki-67 staining in cancerous tissues was significantly associated with tumor grades and distant metastasis of cancer bladder. Moreover, Bertz et al (2014b) suggested that the CK20 was a reliable indicator of biologic aggressiveness and may contribute to decision making on therapeutic strategy for pT1 bladder carcinomas.…”